<prompt> Cabergoline is the drug of choice forParkinsonismAlzheimers diseaseProlactinomaGalactorrhea  <response>: C Prolactinoma Cabergoline: Cabergoline is an ergot derivative. FDA-approved for the treatment of hyperprolactinemia. Cabergoline has been linked to valvular heart disease, an effect proposed to reflect agonist activity at the serotonin 5-HT2B receptor. Dopamine agonist, bromocriptine mesylate, is often the initial drug of choice and may require high doses to achieve clinical improvement and shrinkage of prolactinomas. It can lower the prolactin level in 70-100 of patients. While the evidence supporting the use of medication therapy first is largely based on uncontrolled observational studies, they do strongly support the use of these medications. Agents other than bromocriptine have been used Eg, Cabergoline, Quinagolide. Cabergoline, in particular, probably is more effective and causes fewer adverse effects than bromocriptine. However, it is much more expensive. Cabergoline is often used in patients who cannot tolerate the adverse effects of bromocriptine or in those who do not respond to bromocriptine. 